DaBomb Protein Biotech Corp. (TPEX:6578)
Taiwan
· Delayed Price · Currency is TWD 15.75
+0.05 (0.32%)
Apr 29, 2026, 1:30 PM CST
DaBomb Protein Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 309.34 | 337.82 | 384.41 | 433.63 | 470.63 | Upgrade
|
| Revenue Growth (YoY) | -8.43% | -12.12% | -11.35% | -7.86% | -22.24% | Upgrade
|
| Cost of Revenue | 240.3 | 269.1 | 337.99 | 414.3 | 448.98 | Upgrade
|
| Gross Profit | 69.04 | 68.73 | 46.43 | 19.33 | 21.65 | Upgrade
|
| Selling, General & Admin | 80.99 | 55.6 | 62.77 | 69.95 | 73.61 | Upgrade
|
| Research & Development | 16.23 | 14.95 | 13.59 | 11.85 | 11.82 | Upgrade
|
| Operating Expenses | 97.22 | 70.55 | 76.36 | 81.8 | 85.42 | Upgrade
|
| Operating Income | -28.18 | -1.82 | -29.93 | -62.47 | -63.77 | Upgrade
|
| Interest Expense | -3.07 | -5.21 | -8.23 | -6.58 | -4.58 | Upgrade
|
| Interest & Investment Income | 1.8 | 5.02 | 6.33 | 2.37 | 2.44 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.52 | 14.89 | -0.82 | 15.68 | -6.86 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.19 | 3.17 | 2.36 | 1.87 | 1.15 | Upgrade
|
| EBT Excluding Unusual Items | -25.75 | 16.05 | -30.29 | -49.13 | -71.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.22 | -0.02 | -0.07 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.16 | 0.04 | -25.59 | 0.05 | - | Upgrade
|
| Asset Writedown | -40.65 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0 | - | - | 0.03 | - | Upgrade
|
| Pretax Income | -66.34 | 16.07 | -55.95 | -49.06 | -71.62 | Upgrade
|
| Income Tax Expense | 3 | 4.43 | 1.08 | -4.39 | -9.17 | Upgrade
|
| Net Income | -69.34 | 11.64 | -57.03 | -44.66 | -62.45 | Upgrade
|
| Net Income to Common | -69.34 | 11.64 | -57.03 | -44.66 | -62.45 | Upgrade
|
| Shares Outstanding (Basic) | 72 | 67 | 54 | 39 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 72 | 72 | 54 | 39 | 32 | Upgrade
|
| Shares Change (YoY) | 0.11% | 34.30% | 38.27% | 19.16% | -0.13% | Upgrade
|
| EPS (Basic) | -0.96 | 0.17 | -1.07 | -1.15 | -1.92 | Upgrade
|
| EPS (Diluted) | -0.96 | 0.17 | -1.07 | -1.15 | -1.92 | Upgrade
|
| Free Cash Flow | -21.04 | 17.32 | -12.37 | -0.29 | -376.35 | Upgrade
|
| Free Cash Flow Per Share | -0.29 | 0.24 | -0.23 | -0.01 | -11.59 | Upgrade
|
| Dividend Per Share | - | 0.170 | 0.550 | 1.000 | - | Upgrade
|
| Dividend Growth | - | -69.09% | -45.00% | - | - | Upgrade
|
| Gross Margin | 22.32% | 20.34% | 12.08% | 4.46% | 4.60% | Upgrade
|
| Operating Margin | -9.11% | -0.54% | -7.79% | -14.41% | -13.55% | Upgrade
|
| Profit Margin | -22.41% | 3.45% | -14.83% | -10.30% | -13.27% | Upgrade
|
| Free Cash Flow Margin | -6.80% | 5.13% | -3.22% | -0.07% | -79.97% | Upgrade
|
| EBITDA | 10.5 | 10.44 | -9.98 | -37.48 | -39.81 | Upgrade
|
| EBITDA Margin | 3.39% | 3.09% | -2.60% | -8.64% | -8.46% | Upgrade
|
| D&A For EBITDA | 38.68 | 12.27 | 19.95 | 25 | 23.96 | Upgrade
|
| EBIT | -28.18 | -1.82 | -29.93 | -62.47 | -63.77 | Upgrade
|
| EBIT Margin | -9.11% | -0.54% | -7.79% | -14.41% | -13.55% | Upgrade
|
| Effective Tax Rate | - | 27.57% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.